[8-K] SELECT MEDICAL HOLDINGS CORP Reports Material Event
Select Medical Holdings Corporation (SEM) filed an 8-K reporting leadership changes. The filing references Item 5.02 and Item 7.01 and includes an exhibit: a press release dated September 2, 2025 announcing the appointment of Mr. Mullin as Chief Executive Officer and noting other changes involving long-tenured leaders. The 8-K indicates the company furnished written communications under Regulation FD and provided the press release as Exhibit 99.1. The disclosure signals a formal CEO transition and related leadership adjustments, documented through the company鈥檚 required SEC communication channels.
Select Medical Holdings Corporation (SEM) ha presentato un modulo 8-K che riporta cambiamenti ai vertici. La comunicazione fa riferimento agli Item 5.02 e 7.01 e comprende un allegato: un comunicato stampa datato 2 settembre 2025 che annuncia la nomina del Sig. Mullin a Chief Executive Officer e segnala altri cambiamenti riguardanti dirigenti di lunga data. L鈥�8-K indica che la societ脿 ha fornito comunicazioni scritte ai sensi del Regulation FD e ha inserito il comunicato stampa come Exhibit 99.1. La divulgazione segnala una formale transizione del CEO e adeguamenti nella leadership, documentati attraverso i canali di comunicazione richiesti dalla SEC.
Select Medical Holdings Corporation (SEM) present贸 un 8-K informando sobre cambios en la direcci贸n. La presentaci贸n hace referencia a los Item 5.02 y 7.01 e incluye un anexo: un comunicado de prensa con fecha 2 de septiembre de 2025 que anuncia el nombramiento del Sr. Mullin como Chief Executive Officer y se帽ala otros cambios entre l铆deres de larga trayectoria. El 8-K indica que la compa帽铆a proporcion贸 comunicaciones escritas conforme a Regulation FD y adjunt贸 el comunicado como Exhibit 99.1. La divulgaci贸n se帽ala una transici贸n formal del CEO y ajustes en la direcci贸n, documentados a trav茅s de los canales de comunicaci贸n requeridos por la SEC.
Select Medical Holdings Corporation (SEM)電� 瓴届榿歆� 氤�瓴届潉 氤搓碃頃橂姅 8-K毳� 鞝滌稖頄堨姷雼堧嫟. 頃措嫻 鞝滌稖靹滊姅 Item 5.02鞕� Item 7.01鞚� 鞏戈笁頃橂┌ 觳秬氍胳劀搿� 2025雲� 9鞗� 2鞚检瀽 氤措弰鞛愲毳� 韽暔頃橁碃 鞛堧姅雿�, 鞐赴鞐愲姅 Mr. Mullin鞚� 斓滉碃瓴届榿鞛�(Chief Executive Officer)搿� 鞛勲獏頃橁碃 鞛リ赴 鞛 欷戩澑 雼るジ 鞛勳洂霌れ潣 氤�瓴届潉 鞎岆Μ瓿� 鞛堨姷雼堧嫟. 8-K電� 須岇偓臧� Regulation FD鞐� 霐半澕 靹滊┐ 旎る雼堨紑鞚挫厴鞚� 鞝滉车頄堨溂氅� 氤措弰鞛愲毳� Exhibit 99.1搿� 鞝滌稖頄堧嫟瓿� 氇呾嫓頃╇媹雼�. 鞚� 瓿奠嫓電� 鞝曥嫕 CEO 鞝勴櫂 氚� 甏�霠� 毽崝鞁� 臁办爼鞚� SEC鞐� 鞖旉惮霅� 毂勲剱鞚� 韱淀暣 氍胳劀頇旊悩鞐堨潓鞚� 鞎岆雼堧嫟.
Select Medical Holdings Corporation (SEM) a d茅pos茅 un formulaire 8-K faisant 茅tat de changements de direction. Le d茅p么t renvoie aux Item 5.02 et 7.01 et comprend une pi猫ce jointe : un communiqu茅 de presse dat茅 du 2 septembre 2025 annon莽ant la nomination de M. Mullin au poste de Chief Executive Officer et signalant d鈥檃utres modifications concernant des cadres de longue date. L鈥�8-K indique que la soci茅t茅 a transmis des communications 茅crites en vertu du Regulation FD et a fourni le communiqu茅 en tant qu鈥橢xhibit 99.1. La divulgation marque une transition formelle du CEO et des ajustements de la direction, document茅s via les canaux de communication requis par la SEC.
Select Medical Holdings Corporation (SEM) reichte ein 8-K ein, das F眉hrungswechsel meldet. Die Einreichung verweist auf Item 5.02 und Item 7.01 und enth盲lt als Anhang eine Pressemitteilung vom 2. September 2025, die die Ernennung von Herrn Mullin zum Chief Executive Officer bekannt gibt und weitere 脛nderungen bei langj盲hrigen F眉hrungskr盲ften nennt. Im 8-K wird angegeben, dass das Unternehmen schriftliche Mitteilungen gem盲脽 Regulation FD bereitgestellt und die Pressemitteilung als Exhibit 99.1 vorgelegt hat. Die Offenlegung signalisiert einen formellen CEO-脺bergang und damit verbundene F眉hrungsanpassungen, dokumentiert 眉ber die von der SEC geforderten Kommunikationskan盲le.
- Appointment of Mr. Mullin as Chief Executive Officer is explicitly disclosed
- Press release provided as Exhibit 99.1, ensuring public disclosure of the leadership change
- Company invoked Regulation FD and relevant 8-K items, indicating compliance with disclosure rules
- None.
Insights
TL;DR: Company reported a CEO appointment and broader leadership changes; this is a material governance event with potential operational implications.
The filing confirms Select Medical named Mr. Mullin as Chief Executive Officer via a press release attached as Exhibit 99.1 and used Regulation FD disclosures. A CEO change is typically material for investors because it can affect strategic direction, capital allocation, and management continuity. The filing references Item 5.02, implying officer/director departure or election activity, but details on specific departures, timing beyond the press release date, and any compensatory arrangements are not provided in the text supplied. Analysts will seek the full press release and any subsequent disclosures for clarity on succession, transition plans, and any severance/change-in-control costs.
TL;DR: Formal SEC disclosure of a CEO appointment and related leadership changes is a governance milestone requiring monitoring of transition details.
The 8-K explicitly attaches a September 2, 2025 press release announcing Mr. Mullin as CEO and notes other changes involving long-tenured leaders. The inclusion of Item 5.02 indicates the company is reporting officer/director departures or elections consistent with governance disclosure rules. The filing also cites Regulation FD channels, suggesting management intends contemporaneous public disclosure. The document provided does not include the press release text or specifics about which leaders are affected, succession timelines, or compensation adjustments, so governance assessment is limited until those items are reviewed.
Select Medical Holdings Corporation (SEM) ha presentato un modulo 8-K che riporta cambiamenti ai vertici. La comunicazione fa riferimento agli Item 5.02 e 7.01 e comprende un allegato: un comunicato stampa datato 2 settembre 2025 che annuncia la nomina del Sig. Mullin a Chief Executive Officer e segnala altri cambiamenti riguardanti dirigenti di lunga data. L鈥�8-K indica che la societ脿 ha fornito comunicazioni scritte ai sensi del Regulation FD e ha inserito il comunicato stampa come Exhibit 99.1. La divulgazione segnala una formale transizione del CEO e adeguamenti nella leadership, documentati attraverso i canali di comunicazione richiesti dalla SEC.
Select Medical Holdings Corporation (SEM) present贸 un 8-K informando sobre cambios en la direcci贸n. La presentaci贸n hace referencia a los Item 5.02 y 7.01 e incluye un anexo: un comunicado de prensa con fecha 2 de septiembre de 2025 que anuncia el nombramiento del Sr. Mullin como Chief Executive Officer y se帽ala otros cambios entre l铆deres de larga trayectoria. El 8-K indica que la compa帽铆a proporcion贸 comunicaciones escritas conforme a Regulation FD y adjunt贸 el comunicado como Exhibit 99.1. La divulgaci贸n se帽ala una transici贸n formal del CEO y ajustes en la direcci贸n, documentados a trav茅s de los canales de comunicaci贸n requeridos por la SEC.
Select Medical Holdings Corporation (SEM)電� 瓴届榿歆� 氤�瓴届潉 氤搓碃頃橂姅 8-K毳� 鞝滌稖頄堨姷雼堧嫟. 頃措嫻 鞝滌稖靹滊姅 Item 5.02鞕� Item 7.01鞚� 鞏戈笁頃橂┌ 觳秬氍胳劀搿� 2025雲� 9鞗� 2鞚检瀽 氤措弰鞛愲毳� 韽暔頃橁碃 鞛堧姅雿�, 鞐赴鞐愲姅 Mr. Mullin鞚� 斓滉碃瓴届榿鞛�(Chief Executive Officer)搿� 鞛勲獏頃橁碃 鞛リ赴 鞛 欷戩澑 雼るジ 鞛勳洂霌れ潣 氤�瓴届潉 鞎岆Μ瓿� 鞛堨姷雼堧嫟. 8-K電� 須岇偓臧� Regulation FD鞐� 霐半澕 靹滊┐ 旎る雼堨紑鞚挫厴鞚� 鞝滉车頄堨溂氅� 氤措弰鞛愲毳� Exhibit 99.1搿� 鞝滌稖頄堧嫟瓿� 氇呾嫓頃╇媹雼�. 鞚� 瓿奠嫓電� 鞝曥嫕 CEO 鞝勴櫂 氚� 甏�霠� 毽崝鞁� 臁办爼鞚� SEC鞐� 鞖旉惮霅� 毂勲剱鞚� 韱淀暣 氍胳劀頇旊悩鞐堨潓鞚� 鞎岆雼堧嫟.
Select Medical Holdings Corporation (SEM) a d茅pos茅 un formulaire 8-K faisant 茅tat de changements de direction. Le d茅p么t renvoie aux Item 5.02 et 7.01 et comprend une pi猫ce jointe : un communiqu茅 de presse dat茅 du 2 septembre 2025 annon莽ant la nomination de M. Mullin au poste de Chief Executive Officer et signalant d鈥檃utres modifications concernant des cadres de longue date. L鈥�8-K indique que la soci茅t茅 a transmis des communications 茅crites en vertu du Regulation FD et a fourni le communiqu茅 en tant qu鈥橢xhibit 99.1. La divulgation marque une transition formelle du CEO et des ajustements de la direction, document茅s via les canaux de communication requis par la SEC.
Select Medical Holdings Corporation (SEM) reichte ein 8-K ein, das F眉hrungswechsel meldet. Die Einreichung verweist auf Item 5.02 und Item 7.01 und enth盲lt als Anhang eine Pressemitteilung vom 2. September 2025, die die Ernennung von Herrn Mullin zum Chief Executive Officer bekannt gibt und weitere 脛nderungen bei langj盲hrigen F眉hrungskr盲ften nennt. Im 8-K wird angegeben, dass das Unternehmen schriftliche Mitteilungen gem盲脽 Regulation FD bereitgestellt und die Pressemitteilung als Exhibit 99.1 vorgelegt hat. Die Offenlegung signalisiert einen formellen CEO-脺bergang und damit verbundene F眉hrungsanpassungen, dokumentiert 眉ber die von der SEC geforderten Kommunikationskan盲le.
FAQ
What did Select Medical (SEM) disclose in this 8-K filing?
When was the CEO appointment for Select Medical announced?
Does the filing specify which long-tenured leaders were changed or departed?
Is there any financial or compensation information included in the filing?
Where can I find the full details of the announcement?
